Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
MB

NASDAQ · MBX

MBX Biosciences, Inc. Common Stock

Healthcare · Biotechnology

$55.87

Up+$1.33 (+2.44%)

Updated Nov 2, 2026, 7:14 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
954.72M
P/E ratio
-12.07
Dividend yield
0.00%
52-week range
$19.95 – $72.64
Volume
667.27K
Avg. volume
1.44M

Price performance · MBX

MBX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

MBX closed at $55.87 after 20 trading sessions, down 4.56% for the selected period.

Last close
$55.87
Period change
-4.56%
Period low
$48.50
Period high
$58.54
Daily close
View OHLC price history
MBX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$53.72$56.57$52.285$55.87667.27K
Oct 29, 2026$54.51$56.18$53.25$54.54257.2K
Oct 28, 2026$52.53$54.55$49.85$54.16258K
Oct 27, 2026$50.24$53.63$50.05$52.97492.99K
Oct 26, 2026$48.93$50.81$47.93$50.29653.05K
Oct 23, 2026$50.15$50.15$47.50$48.50581.56K
Oct 22, 2026$53.50$54.99$50.25$50.46631.69K
Oct 21, 2026$53.87$56.20$53.43$53.93400.36K
Oct 20, 2026$52.56$55.00$51.05$53.50808.03K
Oct 19, 2026$49.70$53.055$49.70$52.48522.21K
Oct 16, 2026$50.69$50.88$49.225$49.61818.92K
Oct 15, 2026$49.15$51.30$48.73$50.71601.77K
Oct 14, 2026$48.02$49.54$47.60$48.82994.42K
Oct 13, 2026$52.04$53.035$48.91$49.00769K
Oct 12, 2026$53.24$54.03$51.89$52.02991.56K
Oct 9, 2026$53.26$53.82$51.885$53.24538.78K
Oct 8, 2026$53.66$53.77$50.42$53.25413.81K
Oct 7, 2026$56.38$58.4999$53.36$54.54357.16K
Oct 6, 2026$58.75$59.225$55.34$56.92366.63K
Oct 5, 2026$58.33$59.26$56.415$58.54583.21K

Latest MBX news

The latest Smart Investors Daily articles mentioning MBX.

Stock researchCompany · Overview

MBX research

Overview

Company profile and research snapshot.

Company profile

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$28.00
Implied upside
—
Analysts
—
MBX recent ratings
DateFirmRatingTarget
Oct 12, 2026StifelBuy—
Oct 2, 2026GuggenheimBuy—
Aug 21, 2026JP MorganOverweight—
Aug 10, 2026Truist SecuritiesBuy—
Jul 29, 2026MizuhoOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 13, 2026

MBX Biosciences to Participate in Upcoming November Investor Conferences

CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferen

Yahoo · Oct 10, 2026

Is MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run?

MBX Biosciences (MBX) drew fresh attention after a year-to-date return of 174%, even as the share price closed at US$53.24 and declined over the past month and the past three months. The recent pullback, with the 7 day share price return down 9.01% and the 30 day move down 15.37%, sits against a year to date share price gain of 74.27% and a 1 year total shareholder return of 257.08%. This indicates that momentum for MBX Biosciences has cooled in the short term after a very strong stretch for...

Yahoo · Oct 10, 2026

MBX Biosciences (MBX) Stock Could Be Above Fair Value As Shares Jumped 257%

MBX Biosciences has seen its share price move sharply over the past year, which puts a spotlight on whether today's valuation lines up with what sits on its balance sheet. With the stock now well above where it started the year, the question is how that market enthusiasm stacks up against its book value. Over the past 12 months, MBX Biosciences has delivered a 257.1% share price gain, which puts real pressure on investors to judge whether the current level is still grounded in its underlying...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By